发布求助
文献互助 智能选刊 最新文献

Global & Regional Health Technology Assessment最新文献

筛选
英文 中文
Costs and benefits in patients with NYHA class III heart failure treated with CardioMEMS in Italy. 意大利 NYHA III 级心力衰竭患者接受 CardioMEMS 治疗的成本和收益。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2024-05-02 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.3018
Andrea Messori, Maria Rita Romeo, Valeria Fadda, Francesca Collini, Sabrina Trippoli
{"title":"Costs and benefits in patients with NYHA class III heart failure treated with CardioMEMS in Italy.","authors":"Andrea Messori, Maria Rita Romeo, Valeria Fadda, Francesca Collini, Sabrina Trippoli","doi":"10.33393/grhta.2024.3018","DOIUrl":"10.33393/grhta.2024.3018","url":null,"abstract":"<p><strong>Background: </strong>CardioMEMS is a device suitable for telemedicine that is currently being evaluated by the Regional Health Technology Assessment (HTA) Committee of Tuscany. Two detailed HTA reports are available in the specialized literature, the results of which need to be transferred to our regional setting. These decisions in Tuscany are made by the so-called Centro Operativo HTA.</p><p><strong>Aim: </strong>To validate, with local cost-effectiveness data, the decision on CardioMEMS that will be made in the Tuscany region.</p><p><strong>Methods: </strong>Two detailed international HTA reports were rearranged and adapted to our regional setting to generate a simplified analysis that could form the basis of our decision. Two willingness-to-pay (WTP) thresholds of €20,000/quality-adjusted life year (QALY) and €50,000/QALY were considered.</p><p><strong>Results: </strong>Based on epidemiological and regulatory information, the target population in Tuscany for this device is 166 cases. The value-based price of CardioMEMS is estimated to be €4,332 and €16,662 at WTP thresholds of 20,000/QALY and 50,000/QALY, respectively. Its current price in Italy is €12,000.</p><p><strong>Conclusion: </strong>In our region, the introduction of CardioMEMS is likely to be gradual, around 50 patients/year (or €0.60 million/year at current price). This example highlights the need to adapt the information published in the international literature to the local context in which the approval decision is made. In this context, simplified analyses are easier to apply than complex Markov models.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"11 ","pages":"105-107"},"PeriodicalIF":0.4,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11067868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dati regionali e loro ruolo nella pianificazione, nella programmazione e nel controllo a livello regionale. 地区数据及其在地区一级的规划、计划编制和控制中的作用。
IF 0.5
Global & Regional Health Technology Assessment Pub Date : 2024-04-25 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.3024
Irene Marzona, Paolo Stella, Gianluca Trifirò, Giovanni Corrao
{"title":"Dati regionali e loro ruolo nella pianificazione, nella programmazione e nel controllo a livello regionale.","authors":"Irene Marzona, Paolo Stella, Gianluca Trifirò, Giovanni Corrao","doi":"10.33393/grhta.2024.3024","DOIUrl":"https://doi.org/10.33393/grhta.2024.3024","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"11 ","pages":"101-104"},"PeriodicalIF":0.5,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11056689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140855318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prontuari Terapeutici Regionali in Italia: stato dell’arte e prospettive future. 意大利的地区治疗方案：技术水平和未来前景。
IF 0.5
Global & Regional Health Technology Assessment Pub Date : 2024-03-08 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2677
Alberto Bortolami, Claudio Jommi, Filippo Bresciani, Luca Piccoli, Elisa Sangiorgi, Giovanna Scroccaro
{"title":"Prontuari Terapeutici Regionali in Italia: stato dell’arte e prospettive future.","authors":"Alberto Bortolami, Claudio Jommi, Filippo Bresciani, Luca Piccoli, Elisa Sangiorgi, Giovanna Scroccaro","doi":"10.33393/grhta.2024.2677","DOIUrl":"https://doi.org/10.33393/grhta.2024.2677","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"11 ","pages":"68-74"},"PeriodicalIF":0.5,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10949060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140178661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Costo per Number Needed to Treat (NNT) di upadacitinib nel trattamento dei pazienti bio-exposed con rettocolite ulcerosa attiva da moderata a grave. 奥达帕替尼治疗生物暴露的中重度活动性溃疡性直肠结肠炎患者的单位治疗人数成本（NNT）。
IF 0.5
Global & Regional Health Technology Assessment Pub Date : 2024-03-07 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2658
Flavio Caprioli, Massimo Claudio Fantini, Francesca Marando, Dario Scaduto, Roberto Ravasio
{"title":"Costo per <i>Number Needed to Treat</i> (NNT) di upadacitinib nel trattamento dei pazienti <i>bio-exposed</i> con rettocolite ulcerosa attiva da moderata a grave.","authors":"Flavio Caprioli, Massimo Claudio Fantini, Francesca Marando, Dario Scaduto, Roberto Ravasio","doi":"10.33393/grhta.2024.2658","DOIUrl":"10.33393/grhta.2024.2658","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"11 ","pages":"55-67"},"PeriodicalIF":0.5,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10926000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140101425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regolamento HTA: come si sta muovendo l’Italia? HTA 法规：意大利在做什么？
IF 0.5
Global & Regional Health Technology Assessment Pub Date : 2024-03-05 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.3025
Francesca Patarnello
{"title":"Regolamento HTA: come si sta muovendo l’Italia?","authors":"Francesca Patarnello","doi":"10.33393/grhta.2024.3025","DOIUrl":"https://doi.org/10.33393/grhta.2024.3025","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"11 ","pages":"51-54"},"PeriodicalIF":0.5,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10915632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140051473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Costo per NNT di upadacitinib nel trattamento dei pazienti con dermatite atopica da moderata a severa in Italia. 意大利奥达帕替尼治疗中重度特应性皮炎患者的每 NNT 成本。
IF 0.5
Global & Regional Health Technology Assessment Pub Date : 2024-02-16 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2728
Andrea Chiricozzi, Antonio Costanzo, Anna Levi, Federica Parretta, Roberto Ravasio
{"title":"Costo per NNT di upadacitinib nel trattamento dei pazienti con dermatite atopica da moderata a severa in Italia.","authors":"Andrea Chiricozzi, Antonio Costanzo, Anna Levi, Federica Parretta, Roberto Ravasio","doi":"10.33393/grhta.2024.2728","DOIUrl":"10.33393/grhta.2024.2728","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"11 ","pages":"38-50"},"PeriodicalIF":0.5,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10877702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139912464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Il burden clinico ed economico delle complicanze della cute peristomale: un’analisi di Activity Based Costing. 肛周皮肤并发症的临床和经济负担：基于活动成本的分析。
IF 0.4
Global & Regional Health Technology Assessment Pub Date : 2024-01-23 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2639
Agostino Fortunato, Filippo Rumi, Massimo Zazzetta, Marco Della Valle, Vincenzo Pedace, Americo Cicchetti
{"title":"Il burden clinico ed economico delle complicanze della cute peristomale: un’analisi di Activity Based Costing.","authors":"Agostino Fortunato, Filippo Rumi, Massimo Zazzetta, Marco Della Valle, Vincenzo Pedace, Americo Cicchetti","doi":"10.33393/grhta.2024.2639","DOIUrl":"10.33393/grhta.2024.2639","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"11 ","pages":"31-37"},"PeriodicalIF":0.4,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10813189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139570373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Il futuro delle forme di distribuzione dei farmaci in regime di Servizio Sanitario Nazionale. 国家医疗卫生服务机构药品配送形式的未来。
IF 0.5
Global & Regional Health Technology Assessment Pub Date : 2024-01-15 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2619
Massimo Medaglia, Giuliano Buzzetti, Marco Cossolo, Paola Deambrosis, Giovanna Scroccaro
{"title":"Il futuro delle forme di distribuzione dei farmaci in regime di Servizio Sanitario Nazionale.","authors":"Massimo Medaglia, Giuliano Buzzetti, Marco Cossolo, Paola Deambrosis, Giovanna Scroccaro","doi":"10.33393/grhta.2024.2619","DOIUrl":"https://doi.org/10.33393/grhta.2024.2619","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"11 ","pages":"17-21"},"PeriodicalIF":0.5,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10792386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139484939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP). 意大利因慢性肾病相关性瘙痒症（CKD-aP）而接受血液透析治疗的患者的医疗资源消耗情况。
IF 0.5
Global & Regional Health Technology Assessment Pub Date : 2024-01-15 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2696
Silvia Calabria, Lucio Manenti, Giulia Ronconi, Carlo Piccinni, Letizia Dondi, Leonardo Dondi, Antonella Pedrini, Immacolata Esposito, Alice Addesi, Filippo Aucella, Nello Martini
{"title":"Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP).","authors":"Silvia Calabria, Lucio Manenti, Giulia Ronconi, Carlo Piccinni, Letizia Dondi, Leonardo Dondi, Antonella Pedrini, Immacolata Esposito, Alice Addesi, Filippo Aucella, Nello Martini","doi":"10.33393/grhta.2024.2696","DOIUrl":"10.33393/grhta.2024.2696","url":null,"abstract":"<p><strong>Background: </strong>Chronic kidney disease-associated pruritus (CKD-aP) affects patients on hemodialysis. This study identified hemodialysis patients presumably affected or not affected by CKD-aP and integrated healthcare costs, from the perspective of the Italian administrative healthcare data.</p><p><strong>Methods: </strong>Through cross-linkage of Italian administrative healthcare data collected between 2015 and 2017 (accrual period) in the database of Fondazione ReS (Ricerca e Salute), patients undergoing in-hospital/outpatient hemodialysis were selected. Cohorts with and without CKD-aP were created based on the presence/absence of CKD-aP-related treatment (according to common clinical practice and guidelines) supplies and assessed in terms of CKD-aP-related treatments and mean healthcare costs per capita paid by the Italian National Health Service (INHS).</p><p><strong>Results: </strong>Of 1,239 people on hemodialysis for ≥2 years, CKD-aP affected 218 patients. Patients with CKD-aP were older and with more comorbidities. During the follow-up year, on average, the INHS spent €37,065 per case, €31,286 per control and € 35,988 per non-CKD-aP subject. High-efficiency dialytic therapies performed to people on hemodialysis with CKD-aP largely weighed on the overall mean annual cost.</p><p><strong>Conclusions: </strong>This real-world study identified patients on chronic hemodialysis potentially treated for CKD-aP. Interestingly, high-efficiency dialysis seems the most frequent and expensive choice for the treatment of CKD-aP. The discovery of appropriate and effective treatments for this condition might offer cost offsets.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"11 ","pages":"22-30"},"PeriodicalIF":0.5,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10792387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139484946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Farmaci orfani in Italia: disponibilità e tempi di accesso a livello regionale. 意大利的 "孤儿药"：地区供应和获取时间。
IF 0.5
Global & Regional Health Technology Assessment Pub Date : 2023-12-28 eCollection Date: 2023-01-01 DOI: 10.33393/grhta.2023.2641
Maria Lucia Marino, Eva Alessi, Aurora Di Filippo, Barbara Polistena, Francesco Macchia, Federico Spandonaro, Francesco Trotta
{"title":"Farmaci orfani in Italia: disponibilità e tempi di accesso a livello regionale.","authors":"Maria Lucia Marino, Eva Alessi, Aurora Di Filippo, Barbara Polistena, Francesco Macchia, Federico Spandonaro, Francesco Trotta","doi":"10.33393/grhta.2023.2641","DOIUrl":"10.33393/grhta.2023.2641","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"10 ","pages":"89-97"},"PeriodicalIF":0.5,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10757301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139073770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信